½ÃÀ庸°í¼­
»óǰÄÚµå
1562242

ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå Àü¸Á(-2030³â) : Áö¿ªº° ºÐ¼® - À¯Çüº°, Ä¡·á¹ýº°, ¿¬·É´ëº°, ÃÖÁ¾ »ç¿ëÀÚº°

North America Myopia Treatment Market Forecast to 2030 - Regional Analysis - by Type, Treatment, Age Group, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 109 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº 2022³â 39¾ï 3,890¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 73¾ï 3,526¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022-2030³â°£ 8.1%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

±Ù½Ã À¯º´·ü Áõ°¡·Î ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ¼ºÀå ÃËÁø

±Ù½Ã À¯º´·üÀÌ Àü ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖ´Â °ÍÀº ½É°¢ÇÑ °øÁߺ¸°Ç ¹®Á¦À̸ç, ƯÈ÷ ¾î¸°ÀÌ¿Í ÀþÀº ¼ºÀÎµé »çÀÌ¿¡¼­ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù ¿¬±¸¿¡ µû¸£¸é 2050³â±îÁö Àü ¼¼°è Àα¸ÀÇ °ÅÀÇ 50%, Áï 50¾ï ¸íÀÌ ±Ù½Ã°¡ µÉ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, ÀÌ´Â ÇöÀç Æò±Õ 30%¿¡¼­ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹¿¡¼­µµ ±Ù½Ã ºóµµ°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ±× ºñÀ²Àº 42%·Î º¸°íµÇ¾î ºÒ°ú 30³â ¸¸¿¡ °ÅÀÇ µÎ ¹è·Î Áõ°¡Çß½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­, µµ½ÃÈ­, µðÁöÅÐ ±â±âÀÇ Àå½Ã°£ »ç¿ë, ¾ß¿Ü ³ëÃâ Á¦ÇÑ µî ±Ù°Å¸® ÀÛ¾÷ÀÇ ±¤¹üÀ§ÇÑ È°µ¿ µî ¿©·¯ ¿äÀÎÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀû ¼ÒÀεµ ÇѸòÀ» ÇÏÁö¸¸, ȯ°æÀû ¿äÀεµ ±Ù½ÃÀ²À» Å©°Ô Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »ýȰ½À°ü°ú ȯ°æÀû ¿äÀÎÀÇ ¿µÇâÀº À¯ÀüÀû °¨¼ö¼º°ú ȯ°æÀû ¿µÇâ »çÀÌÀÇ º¹ÀâÇÑ »óÈ£ ÀÛ¿ë¿¡ ´ëÇÑ ÀÌÇØ¸¦ ³ôÀ̰í, ±Þ¼ºÀåÇÏ´Â °øÁߺ¸°Ç ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇÑ Á¾ÇÕÀûÀÎ Àü·«ÀÇ Çʿ伺À» ´õ¿í °­Á¶Çϰí ÀÖ½À´Ï´Ù. ±Ù½Ã À¯º´·üÀÌ °è¼Ó Áõ°¡ÇÔ¿¡ µû¶ó °íµµ ±Ù½Ã ¹× °ü·Ã ¾È°úÀû ÇÕº´ÁõÀÇ Àå±âÀûÀÎ ¿µÇâÀ» ÁÙÀ̱â À§ÇÑ Àû±ØÀûÀÎ °³ÀÔ, °øÁߺ¸°Ç Ä·ÆäÀÎ ¹× Çõ½ÅÀûÀÎ Ä¡·á Á¢±Ù¹ý °³¹ß¿¡ ´ëÇÑ Á߿伺ÀÌ °­Á¶µÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ´Ù°¢ÀûÀÎ ¼¼°è °Ç°­ ¹®Á¦¸¦ ÇØ°áÇÏ´Â µ¥ ÀÖ¾î ±× Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå °³¿ä

ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹Àº ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÃÀå ¼ºÀåÀº ±Ù½Ã °ü·Ã ½Ã·Â ÀúÇÏ Áõ°¡¿Í Ä¡·áµÇÁö ¾ÊÀº ±Ù½Ã·Î ÀÎÇÑ ¿ø°Å¸® ½Ã·Â Àå¾Ö ¹ß»ý·ü Áõ°¡ µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, ´« °Ç°­¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿ø Áõ°¡¿Í ±â¼ú ¹ßÀüÀº ºÏ¹Ì ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº ÇâÈÄ ¸î ³âµ¿¾È Å« ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±Ù½Ã À¯º´·üÀº ÃÖ±Ù ¸î ³âµ¿¾È Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖÀ¸¸ç, 2023³â ±Ù½Ã ¿¬±¸¼Ò°¡ ¹ßÇ¥ÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹ÀÇ ±Ù½Ã À¯º´·üÀº 42%·Î º¸°íµÇ¾î 30³â ¸¸¿¡ °ÅÀÇ µÎ ¹è·Î Áõ°¡Çß½À´Ï´Ù. ¶ÇÇÑ ±Ù½Ã¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁø °Íµµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Brian Holden Vision Institute°¡ ÁÖÃÖÇÏ´Â 2024³â ±Ù½Ã ÀÎ½Ä ÁÖ°£Àº Review of Myopia Management¸¦ °ø½Ä °øµ¿ ÈÄ¿ø»ç·Î ¼±Á¤Çß½À´Ï´Ù. À̹ø Çù·ÂÀº 2024³â 5¿ù 13ÀϺÎÅÍ 19ÀϱîÁö ±¹³»¿Ü¿¡¼­ ¿­¸®´Â ±Ù½Ã ÀÎ½Ä ÁÖ°£ÀÌ ´õ ¸¹Àº »ç¶÷µé¿¡°Ô ´Ù°¡°¥ ¼ö ÀÖµµ·Ï Áö¿øÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ±Ù½Ã´Â ¹é³»Àå, ³ì³»Àå µî ´Ù¸¥ ¾ÈÁúȯÀÇ ¹ßº´ À§ÇèÀ» ³ôÀÌ´Â µî ±Ù½Ã¿¡ µû¸¥ À§Ç輺À» ÀνÄÇÏ´Â »ç¶÷µéÀÌ ´Ã°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ±Ù½Ã¸¦ ¿¹¹æÇϰųª ÁøÇàÀ» Áö¿¬½ÃŰ´Â È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ±Ù½Ã Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¶Ç ´Ù¸¥ ¿äÀÎÀº ÷´Ü ±â¼ú ¹× Ä¡·á¹ýÀÌ °³¹ßµÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÇöÀç ±Ù½Ã Ä¡·á´Â ±³Á¤ ·»Áî, °¢¸· Àý»è¼ú, ¾à¸®ÇÐÀû Ä¡·á µî ´Ù¾çÇÑ ±Ù½Ã Ä¡·á¹ýÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº Á¡Á¡ ´õ Á¤±³ÇØÁö°í È¿°úÀûÀÌ µÇ¾î ±Ù½Ã Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ¼Ò¾Æ ±Ù½Ã À¯º´·ü Áõ°¡´Â ¹Ì±¹ ±Ù½Ã Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ±Ù½Ã Áø´ÜÀ» ¹Þ´Â ¾î¸°À̰¡ Áõ°¡ÇÔ¿¡ µû¶ó ±Ù½Ã ¿¹¹æ ¹× ÁøÇàÀ» Áö¿¬½ÃŰ´Â È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¼Ò¾Æ¿¡ ƯȭµÈ »õ·Î¿î Ä¡·á¹ý ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î ¹Ì±¹ ±Ù½Ã Ä¡·á ½ÃÀåÀº ±Ù½Ã Áõ»óÀ» ÀνÄÇÏ´Â »ç¶÷µéÀÌ Áõ°¡Çϰí È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÇâÈÄ ¸î ³âµ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ¼¼ºÐÈ­

ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº À¯Çü, Ä¡·á¹ý, ¿¬·É´ë, ÃÖÁ¾ »ç¿ëÀÚ ¹× ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.

À¯Çüº°·Î ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº °­µµ ±Ù½Ã, ÅðÇ༺ ±Ù½Ã, ÁøÇ༺ ±Ù½Ã·Î ±¸ºÐµÇ¸ç, 2022³â ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå Á¡À¯À²Àº °­µµ ±Ù½Ã ºÐ¾ß°¡ °¡Àå Å« °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

Ä¡·á Ãø¸é¿¡¼­ ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº Àú¿ë·® ¾ÆÆ®·ÎÇÉ Á¡¾ÈÁ¦, ÄÜÅÃÆ®·»Áî, °¢¸· Àý»è¼ú, ±¼Àý ±³Á¤ ¼ö¼ú·Î ±¸ºÐµÇ¸ç, 2022³â ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå Á¡À¯À²Àº Àú¿ë·® ¾ÆÆ®·ÎÇÉ Á¡¾ÈÁ¦ ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù. ¶ÇÇÑ, ±¼Àý±³Á¤¼ö¼ú ºÎ¹®Àº ¶ó½Ä ¹× PRK·Î ¼¼ºÐÈ­µË´Ï´Ù.

¿¬·É´ëº°·Î ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº ¼ºÀÎ ±Ù½Ã¿Í ¼Ò¾Æ ±Ù½Ã·Î ³ª´µ¸ç, 2022³â ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå Á¡À¯À²Àº ¼ºÀÎ ±Ù½Ã ºÎ¹®ÀÌ ´õ Ŭ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚ¿¡ µû¶ó ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, Àü¹® Ŭ¸®´Ð, ±¼Àý ±³Á¤ ¼ö¼ú¼¾ÅÍ·Î ºÐ·ùµÇ¸ç, 2022³â ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå Á¡À¯À²Àº º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ºÐ·ùµË´Ï´Ù. ¹Ì±¹ÀÌ 2022³â ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå Á¡À¯À²À» µ¶Â÷ÁöÇß½À´Ï´Ù.

Bausch Health Companies Inc, Alcon AG, CooperVision Inc, Johnson &Johnson Vision Care Inc, Topcon Healthcare Solutions Inc, Ziemer Ophthalmic Systems AG, Nidek Co Ltd, Eyes Vision SL, Haag-Streit AG, Carl Zeiss AG µîÀÌ ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷µéÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ±¸µµ

  • PEST ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®

Á¦5Àå ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ÇâÈÄ µ¿Çâ
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ

Á¦6Àå ±Ù½Ã Ä¡·á ½ÃÀå-ºÏ¹Ì ½ÃÀå ºÐ¼®

Á¦7Àå ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ºÐ¼® : À¯Çüº°

  • °­µµ ±Ù½Ã
  • º¯¼º ±Ù½Ã
  • ÁøÇ༺ ±Ù½Ã

Á¦8Àå ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ºÐ¼® : Ä¡·á¹ýº°

  • Àú¿ë·® ¾ÖÆ®·ÎÇÉ Á¡¾È¾à
  • ±¼Àý ±³Á¤ ¼ö¼ú
  • ÄÜÅÃÆ®·»Áî
  • Ortho-K

Á¦9Àå ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ºÐ¼® : ¿¬·ÉÃþº°

  • ¼ºÀÎ ±Ù½Ã
  • ¼Ò¾Æ ±Ù½Ã

Á¦10Àå ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø ¹× Ŭ¸®´Ð
  • Àü¹® Ŭ¸®´Ð
  • ±¼Àý±³Á¤ ¼ö¼ú¼¾ÅÍ

Á¦11Àå ºÏ¹ÌÀÇ ±Ù½Ã Ä¡·á ½ÃÀå : ±¹°¡º° ºÐ¼®

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ

Á¦12Àå ¾÷°è »óȲ

  • ±Ù½Ã Ä¡·á ½ÃÀå ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«
    • ¼ºÀå Àü·«

Á¦13Àå ±â¾÷ °³¿ä

  • Bausch Health Companies Inc
  • Alcon AG
  • CooperVision Inc
  • Johnson & Johnson Vision Care Inc
  • Topcon Healthcare Solutions Inc
  • Ziemer Ophthalmic Systems AG
  • Nidek Co Ltd
  • Eyes Vision SL
  • Haag-Streit AG
  • Carl Zeiss AG

Á¦14Àå ºÎ·Ï

LSH 24.10.31

The North America myopia treatment market was valued at US$ 3,938.90 million in 2022 and is expected to reach US$ 7,335.26 million by 2030; it is estimated to register a CAGR of 8.1% from 2022 to 2030.

Rising Prevalence of Myopia Fuels North America Myopia Treatment Market

The rising prevalence of myopia globally represents a significant public health concern, with increasing incidences observed among children and young adults, particularly. A recent study estimated that by 2050, nearly 50% of the world's population-or 5 billion people-will be myopic, up from the current average of 30%. The frequency of myopia is also increasing in the US; it has been reported to be 42%, nearly doubling in just three decades. Multiple factors contribute to this trend, including lifestyle changes, increased urbanization, and extensive near-work activities, such as prolonged use of digital devices and limited outdoor exposure. While genetic predisposition plays a role, environmental factors also contribute to escalating the rates of myopia substantially. The impact of these lifestyle and environmental factors has led to an enhanced understanding of the complex interplay between genetic susceptibility and environmental influences, further underscoring the need for comprehensive strategies to address this burgeoning public health issue. As the prevalence of myopia continues to rise, there is a growing emphasis on developing proactive interventions, public health campaigns, and innovative treatment approaches to mitigate the long-term implications of high myopia and its associated ocular complications, thereby emphasizing the importance of addressing this multifaceted global health challenge.

North America Myopia Treatment Market Overview

The North America myopia treatment market has been segmented into the US, Canada, and Mexico. The US holds the largest share of the North America myopia treatment market. The market growth in the US will be due to factors such as the growing myopia-related occurrences of vision loss and rising incidence of distant vision impairment from untreated myopia. Furthermore, the rising government support for eye health and technological advancements are prominent factors propelling the North America market growth.

The US myopia treatment market is expected to experience significant growth in the coming years. The prevalence of myopia has been increasing in recent years, which is driving the demand for effective treatments. The US has reported a prevalence of 42%, nearly doubling in just three decades, according to data released by the Myopia Institute in 2023. Furthermore, increasing awareness about myopia is also driving market growth. For instance, the Brien Holden Vision Institute's 2024 Myopia Awareness Week has selected Review of Myopia Management as its official co-sponsor. The collaboration will assist in expanding the reach of Myopia Awareness Week, which is scheduled for domestically and internationally, May 13-19, 2024. More people are becoming aware of the risks associated with myopia, such as an increased risk of developing other eye conditions-cataracts and glaucoma. This has led to a greater demand for effective treatments that can help prevent or slow down the progression of myopia. Another factor driving the growth of the myopia treatment market in the US is the availability of advanced technologies and treatments. Various treatments for myopia are now available, including corrective lenses, orthokeratology, and pharmacological treatments. These treatments are becoming increasingly sophisticated and effective, helping drive demand for myopia treatment. Finally, the growing prevalence of myopia among children is also driving the growth of the myopia treatment market in the US. As more children are diagnosed with myopia, there is a greater need for effective treatments that can help prevent or slow down its progression. This has led to increased investment in research and development of new treatments specifically designed for children. Overall, the US myopia treatment market is expected to grow in the coming years as more people become aware of the condition and demand for effective treatments increases.

North America Myopia Treatment Market Revenue and Forecast to 2030 (US$ Million)

North America Myopia Treatment Market Segmentation

The North America myopia treatment market is categorized into type, treatment, age group, end user, and country.

Based on type, the North America myopia treatment market is segmented into high myopia, degenerative myopia, and progressive myopia. The high myopia segment held the largest North America myopia treatment market share in 2022.

In terms of treatment, the North America myopia treatment market is segmented into low-dose atropine eye drops, contact lenses, ortho-k, and refractive surgery. The low-dose atropine eye drops segment held the largest North America myopia treatment market share in 2022. Furthermore, the refractive surgery segment is subcategorized into LASIK and PRK.

By age group, the North America myopia treatment market is bifurcated into adult myopia and childhood myopia. The adult myopia segment held a larger North America myopia treatment market share in 2022.

Based on end user, the North America myopia treatment market is categorized into hospitals and clinics, specialty clinics, and refractive surgery centers. The hospitals and clinics segment held the largest North America myopia treatment market share in 2022.

Based on country, the North America myopia treatment market is categorized into the US, Canada, and Mexico. The US dominated the North America myopia treatment market share in 2022.

Bausch Health Companies Inc, Alcon AG, CooperVision Inc, Johnson & Johnson Vision Care Inc, Topcon Healthcare Solutions Inc, Ziemer Ophthalmic Systems AG, Nidek Co Ltd, Eyes Vision SL, Haag-Streit AG, and Carl Zeiss AG. are some of the leading companies operating in the North America myopia treatment market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Myopia Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Market Share Analysis, By Companies

5. North America Myopia Treatment Market - Key Market Dynamics

  • 5.1 North America Myopia Treatment Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Myopia
    • 5.2.2 Increased Awareness of Myopia Treatment
  • 5.3 Market Restraints
    • 5.3.1 Lack of Skilled Professionals
  • 5.4 Market Opportunities
    • 5.4.1 Rising Availability of Advanced Technologies for Treating the Targeted Myopia
  • 5.5 Future Trends
    • 5.5.1 Application of Artificial Intelligence in Myopia Treatment
  • 5.6 Impact of Drivers and Restraints:

6. Myopia Treatment Market - North America Market Analysis

7. North America Myopia Treatment Market Analysis - by Type

  • 7.1 High Myopia
    • 7.1.1 Overview
    • 7.1.2 High Myopia: North America Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Degenerative Myopia
    • 7.2.1 Overview
    • 7.2.2 Degenerative Myopia: North America Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Progressive Myopia
    • 7.3.1 Overview
    • 7.3.2 Progressive Myopia: North America Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Myopia Treatment Market Analysis - by Treatment

  • 8.1 Low-Dose Atropine Eye Drops
    • 8.1.1 Overview
    • 8.1.2 Low-Dose Atropine Eye Drops: North America Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.2 Refractive Surgery
    • 8.2.1 Overview
    • 8.2.2 Refractive Surgery: North America Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.2.3 LASIK
    • 8.2.4 PRK
  • 8.3 Contact Lenses
    • 8.3.1 Overview
    • 8.3.2 Contact Lenses: North America Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Ortho-K
    • 8.4.1 Overview
    • 8.4.2 Ortho-K: North America Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Myopia Treatment Market Analysis - by Age Group

  • 9.1 Adult Myopia
    • 9.1.1 Overview
    • 9.1.2 Adult Myopia: North America Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.2 Childhood Myopia
    • 9.2.1 Overview
    • 9.2.2 Childhood Myopia: North America Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Myopia Treatment Market Analysis - by End User

  • 10.1 Hospitals and Clinics
    • 10.1.1 Overview
    • 10.1.2 Hospitals and Clinics: North America Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.2 Specialty Clinics
    • 10.2.1 Overview
    • 10.2.2 Specialty Clinics: North America Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Refractive Surgery Centers
    • 10.3.1 Overview
    • 10.3.2 Refractive Surgery Centers: North America Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)

11. North America Myopia Treatment Market - Country Analysis

  • 11.1 North America
    • 11.1.1 North America Myopia Treatment Market
    • 11.1.2 North America: Myopia Treatment Market - Revenue and Forecast Analysis - by Country
      • 11.1.2.1 North America: Myopia Treatment Market - Revenue and Forecast Analysis - by Country
      • 11.1.2.2 US
      • 11.1.2.3 US: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.2.3.1 US: Myopia Treatment Market Breakdown, by Type
        • 11.1.2.3.2 US: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.2.3.3 US: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.2.3.4 US: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.2.3.5 US: Myopia Treatment Market Breakdown, by End User
      • 11.1.2.4 Canada
      • 11.1.2.5 Canada: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.2.5.1 Canada: Myopia Treatment Market Breakdown, by Type
        • 11.1.2.5.2 Canada: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.2.5.3 Canada: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.2.5.4 Canada: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.2.5.5 Canada: Myopia Treatment Market Breakdown, by End User
      • 11.1.2.6 Mexico
      • 11.1.2.7 Mexico: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.2.7.1 Mexico: Myopia Treatment Market Breakdown, by Type
        • 11.1.2.7.2 Mexico: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.2.7.3 Mexico: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.2.7.4 Mexico: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.2.7.5 Mexico: Myopia Treatment Market Breakdown, by End User

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Myopia Treatment Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Bausch Health Companies Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Alcon AG
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 CooperVision Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Johnson & Johnson Vision Care Inc
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Topcon Healthcare Solutions Inc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Ziemer Ophthalmic Systems AG
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Nidek Co Ltd
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Eyes Vision SL
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Haag-Streit AG
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Carl Zeiss AG
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦